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Abstract: The goal in managing patients with epilepsy is complete seizure freedom. 
Pharmacotherapeutic management of epilepsy is complicated by multiple syndromes, inter-
individual differences in drug sensitivities, inter-individual differences in drug disposition, 
and drug interactions. Most anti-epileptic drugs (AEDs) have a therapeutic window with only 
a 2- to 3-fold concentration range. Extended release formulations offer advantages over their 
immediate release counter parts with less ﬂ  uctuation in the serum concentration vs time curve 
and improved compliance. However, missed doses are more likely to result in prolonged “sub-
therapeutic serum concentrations”. Best clinical outcome may sometimes require twice daily 
dosing of extended release formulations even though approved for once daily dosing, as this 
optimally balances pharmacokinetics against compliance. Lamotrigine (LTG) is a broad spec-
trum AED with efﬁ  cacy in partial and generalized epilepsy syndromes and good tolerability. 
Its metabolism is affected by co-medications which may be inducing, neutral or inhibiting of 
hepatic glucuronidation. Furthermore, though the average half-life in monotherapy is about 
24 hours, there is a large inter-individual variation that may, including the extremes, approach 
a range of 10-fold. LTG-XR is expected to decrease ﬂ  uctuation of serum concentration in the 
presence of hepatic inducing or neutral drugs. However, optimal clinical beneﬁ  t in some patients 
may require twice daily dosing when metabolism is rapid.
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Introduction to management issues in epilepsy
Epilepsy is a common neurologic disorder affecting about 1% of the population 
(Hauser et al 1993). Pharmacotherapy with anti-epileptic drugs (AEDs) remains 
the major treatment modality for epilepsy. Management of epilepsy differs from the 
treatment of other chronic diseases in that a single breakthrough event has a major 
negative effect on quality of life (Gilliam 2002). Complete control of seizures is 
necessary as a single seizure impacts negatively on patient quality of life and inde-
pendence. As an example, a single seizure usually limits driving privileges for a 
minimum of 3 months. Management of epilepsy is further complicated by variables 
such as: multiple epilepsy syndromes with varied pharmacosensitivities, inter-
individual differences within a syndrome, and inter-and intra-individual differences 
in AED disposition.
This review will sequentially overview: therapeutic management issues in epilepsy, 
role of extended release formulations, clinical outcomes with currently available 
extended release formulations, lamotrigine (LTG) and LTG extended release (-XR) 
pharmacokinetics, LTG efﬁ  cacy in epilepsy syndromes, LTG safety and tolerability, 
LTG impact on quality of life, and a summary of the place of LTG- XR in epilepsy 
management.Therapeutics and Clinical Risk Management 2008:4(5) 1036
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Management issues in epilepsy
Epilepsy syndromes
Epilepsy is actually a group of disorders sharing the occurrence 
of unprovoked seizures. Over 30 epilepsy syndromes were 
described by the Commission on Classiﬁ  cation and Termi-
nology of The International League Against Epilepsy (1989) 
with varied seizure expression, age of onset, pharmacologic 
sensitivity, and prognosis. The initial categorization usually 
begins with determination of partial (focal) or generalized 
(simultaneous bihemispheric) onset. Generalized epilepsies 
may be idiopathic with a good prognosis and include the syn-
dromes of childhood absence, juvenile absence, and juvenile 
myoclonic epilepsy (Valentin et al 2007). These syndromes 
are genetically based and to date underlying alterations of ion 
channels and neurotransmitter receptors that modulate synap-
tic transmission have been identiﬁ  ed as the underlying cause 
(Helbig et al 2008). Generalized epilepsies may be symptomatic 
due to a broad range of genetic or catastrophic cerebral insults 
with a poor overall prognosis and include syndromes such as 
infantile spasms, Lennox-Gastaut, and progressive myoclonic 
epilepsies (Duchowny and Harvey 1996). Partial epilepsies 
have focal onset of seizures usually from the temporal or frontal 
lobes and less commonly from the parietal or occipital lobes. 
Etiologies of partial epilepsies are varied including mesial 
temporal sclerosis, cortical dysgenesis, vascular malformations, 
tumors, and in a minority primary genetic defects.
AEDs may be effective in select syndromes or may even 
worsen certain epilepsy syndromes and then are termed 
“narrow spectrum” (Genton 2000). Others are likely to be 
effective in many epilepsy syndromes and are often referred 
to as “broad spectrum”. Management is further complicated 
in that our knowledge of syndromes remains quite super-
ﬁ  cial and in therapeutics for a single epilepsy syndrome a 
drug might work for one individual but another drug may 
be required for seizure freedom in another. To date, there 
is no way to pre-identify an individual’s AED sensitivity. 
Serum concentrations needed for seizure control also vary 
signiﬁ  cantly across individuals (Schmidt and Haenel 1984) 
which has led to the term “individual therapeutic reference 
concentration” (Johannessen and Tomson 2006).
Epilepsy pharmacotherapeutics
Currently, more than 12 AEDs are available with mechanism(s) 
of action very incompletely understood. Most have been 
approved in the last decade. Use-dependent voltage-dependent 
sodium channel blockade is a common action of numerous 
AEDs including early drugs such as phenytoin and carbam-
azepine (Rogawski and Löscher 2004; Perucca 2005a). LTG is 
often simply categorized as a sodium channel blocker (Lang 
et al 1993). Inconsistent with this mechanism of action, LTG 
has a broad spectrum of activity in animal models and in 
current clinical use. LTG actions on high voltage activated 
calcium currents (Hainsworth et al 2001), hyperpolarization 
activated inward current (I h) (Poolos et al 2002), potassium 
currents (Huang et al 2004), and even nicotinic receptor chan-
nels are reported (Valles et al 2007). Many of the AEDs mar-
keted over the last 15 years have had multiple sites of action 
identiﬁ  ed (Rogawski and Löscher 2004; Perucca 2005a).
Most patients with epilepsy, nearly two-thirds, respond to 
the ﬁ  rst drug or second AED tried (Kwan and Brodie 2000). 
However, the pivotal clinical trials leading to initial approval 
of an AED are done in highly intractable adult patients with 
partial epilepsy and a severe seizure burden (about one seizure 
per week) and who have failed multiple AEDs. Post-approval 
studies are then extended to include children with a similar 
spectrum of epilepsy. Monotherapy trials in Europe study 
the more typical patient with non-intractable epilepsy. These 
studies have failed to show differences in efﬁ  cacy across 
AEDs, with most subjects becoming seizure free at low doses. 
However, AEDs have differed in terms of tolerability in this 
study design (Kwan and Brodie 2003). Few controlled trials 
of AEDs for other speciﬁ  c epilepsy syndromes exist.
In choosing an AED for a patient the major considerations 
are the triad: ease of use, efﬁ  cacy, and tolerability. Ease of 
use considerations includes rapidity of titration rate, lack of 
serious idiosyncratic reactions, and lack of potential drug 
interactions. Efﬁ  cacy includes consideration of the under-
lying epilepsy syndrome, and in situations of uncertainty 
regarding the speciﬁ  c syndrome, broad spectrum AEDs 
have advantages. Required serum concentrations of AEDs 
are often lower for generalized epilepsy syndromes when 
compared to partial (Schmidt and Haenel 1984). Tolerability 
includes dose-dependent side effects common to AEDs as 
a therapeutic class, such as dizziness, fatigue, unsteadiness, 
decreased concentration, and visual blurring. Side effects 
may be speciﬁ  c to an AED and may be beneﬁ  cial, ie, weight 
loss, or harmful, ie, impaired memory.
Epilepsy pharmacokinetic parameters
The pharmacokinetic parameters of an AED impact on both 
efﬁ  cacy and tolerability. Most AEDs have a small therapeu-
tic window so that with a two to three fold change in serum 
concentration, seizures may become controlled but adverse 
events appear (Johannessen et al 2003).
Trough serum concentrations (Cmin) may put individu-
als at increased risk of seizures whereas AED peak serum Therapeutics and Clinical Risk Management 2008:4(5) 1037
Epilepsy and lamotrigine
concentrations (Cmax) may lead to adverse events. A clear goal 
of therapy would be to maintain the AED serum concentra-
tion vs time curve in a narrow range without ﬂ  uctuations. 
This scenario is also described as a ﬂ  at serum concentration 
time curve. Integration of the time curve gives the area under 
the curve (AUC) that measures overall drug exposure. Of 
course, the AED concentration time curve in serum may not 
be super imposable upon cerebrospinal ﬂ  uid or extracellular 
brain concentration vs time curves and this type of data is 
usually quite limited .
Half-life is an important pharmacokinetic variable. Drugs 
with short half-lives need to be taken 2, 3, or even 4 times per 
day to maintain peak and trough serum concentrations within 
a therapeutic window. Regimens with frequent daily dosing 
are very inconvenient and are associated with increased medi-
cation non-adherence. Non-adherence is inversely related to 
the number of daily doses. Claxton et al (2001) reviewed 76 
studies and found a mean compliance of 71% for all dosing 
regimens combined that declined as the number of doses per 
day increased: 1 dose = 79%, 2 doses = 69%, 3 doses = 65%, 
and 4 doses 51% adherence. The difference between once 
and twice daily did not reach statistical signiﬁ  cance though 
the difference between once and three times and once and 
four times per day did. Cramer et al (2002) showed that 72% 
of epilepsy patients missed doses and 45% reported having 
a seizure after a missed dose.
Finally, medication non-adherence (Osterberg and Blaschke 
2005) and seizures result in increased health care utilization 
and cost. Begley et al (1994) detailed a model of the cost of 
epilepsy, including medical care and time lost from work, based 
on incidence and prognosis. Cost in 1990 dollars per patient 
was lowest for patients with remission after diagnosis and treat-
ment, US $4,272, and highest for persons with intractable and 
frequent seizures, US $138,602 (Begley et al 1994). Population 
based studies from Europe have shown average annual health 
care costs of US $100 to US $2,000 for inactive cases, US $900 
to US $3,000 for active cases and a 2- to 7-fold increase in cost 
for active cases with frequent seizures compared with active 
cases with few (Begley and Beghi 2002). A recent retrospective 
analysis of a managed care population revealed that 39% of 
patients were non-adherent based on AED reﬁ  lls and that this 
was associated with increased emergency room and in-patient 
hospital stays costing US $260 and US $1,799, respectively, 
per patient per year (Davis et al 2008).
Role of extended release formulations
The goal of extended release formulations is to take drugs 
with short half-lives and develop formulations with a 
“pseudo-long half-life” that allow once or twice daily dosing 
with near constant (ﬂ  at) serum concentration vs time curves 
compared with the rapid release formulation, thus resulting 
in improved management. Firstly, the decreased peak serum 
concentration seen with use of extended release formulations 
is expected to decrease dose-dependent side effects that are 
often maximal several hours after an oral dose. Secondly, 
in theory the increased trough concentration should lead 
to improved seizure control. Thirdly, seizure control might 
be improved with extended release formulations by allow-
ing increase of dose, bringing the mean steady state serum 
concentration closer to the peak value previously achieved 
with the immediate release formulation. Fourthly and ﬁ  nally, 
compliance is expected to improve with once or twice daily 
dosing as discussed in the preceding paragraph (Sommerville 
2006; Verotti et al 2007). Patients often prefer once daily 
doing. One potential shortcoming of once daily dosing is that 
a missed dose may be more likely to result in a seizure. This 
is because the missed dose will result in a rapid decline in 
serum concentration based on the unmasking of the true short 
half-life of the AED (Table 1) (Levy 1994; Bialer 2007). For 
this reason, it has been argued that dosing extended release 
formulations, that are “approved” for once daily dosing, 
twice daily in many situations offers the highest probability 
of long-term seizure control based on improved therapeutic 
coverage that outweighs the modest decline of adherence 
(Bialer 2007). The increased compliance should be weighed 
against the impact of omitted dose(s) (Levy 1994). From a 
(theoretical) pharmacokinetic perspective, unless magnitude 
of non-compliance is reduced by more than two-thirds when 
a medication regimen is taken from three times a day to once 
a day dosing (assuming half-life of 12 hours), the increased 
compliance is unlikely to be advantageous and may actually 
be counter-productive in minimizing the occurrence of sub-
therapeutic drug concentrations (Levy 1994). Non-adherence 
and subthreshold AED serum concentrations do relate to the 
Table 1 Comparison of extended release to immediate release 
formulations
Potential beneﬁ  ts
  Lower maximum blood concentration → improved tolerability
  Increase minimum blood concentration → improved seizure control
 Increase  dose  → improve seizure control
  Patient preference for simpliﬁ  ed dosing
   Improved medication adherence (beneﬁ  t may be offset by impact of a 
missed dose)
Potential harm
   Impact of missed doses on serum concentration → seizure 
breakthroughTherapeutics and Clinical Risk Management 2008:4(5) 1038
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occurrence of breakthrough seizures. A recent observational 
study of AED post-ictal serum concentration, found a level 
less than half of the individual baseline serum concentration 
of AED in 44.3% of seizures (Specht et al 2003).
The development of extended release formulations is 
driven by the above described potential clinical beneﬁ  t as 
well as the potential for patent extensions and marketing 
advantages. AEDs are also often used for psychiatric indi-
cations where once a day dosing may be especially critical 
for medication adherence (Rogawski and Löscher 2004; 
Johannessen Landmark 2008). Extended release formulations 
currently exist for phenytoin, carbamazepine, and valproic 
acid. Extended release formulations of lamotrigine, oxcar-
bazepine, and levetiracetam are under development. Success-
ful development requires demonstration that the compounds 
are therapeutically equivalent (Sommerville 2006).
Outcomes with currently released 
extended formulations
Clinical outcome measures comparing extended release to 
immediate release formulations have included pharmacoki-
netic variables to assess bioequivalence and clinical measures 
of seizure frequency, adverse event frequency, patient pref-
erence, and quality of life measures. Two extended release 
formulations of carbamazepine indicated for twice daily 
dosing are marketed in the US: a capsule with three bead 
types each having a different rate of release (Carbatrol®; 
Shire) and an osmotic-release delivery system (Tegretol® 
XR; Novartis). Clinical development included testing in 
double-blind crossover studies demonstrating pharmaco-
kinetic bioequivalence and no signiﬁ  cant differences in 
seizure frequency but with improvements in adverse events, 
55% for immediate release vs 13% for extended release, 
and patient preference for decreased dosing (Canger et al 
1990; Tegretol OROS Study Group 1995). Pharmacokinetic 
beneﬁ  t also probably came from ﬂ  attening the serum con-
centration time curve of the shorter half-life carbamazepine 
active metabolite, carbamazepine 10,11 epoxide (McKee 
et al 1993). Subsequent unblinded, open-label studies have 
also observed decreased adverse events (Miller et al 2004, 
Ficker et al 2005), improved quality of life (Mirza et al 1998; 
Ficker et al 2005) and a statistically signiﬁ  cant decrease in 
the rate of seizures (Hogan et al 2003; Ficker et al 2005). 
The ability to modestly increase total daily dose using the 
extended release formulation was also demonstrated (Canger 
et al 1990; Miller et al 2004).
Divalproex extended release (Depakote® ER; Abbott), 
approved for once daily doing, is a tablet of sustained release 
hydrophilic matrix technology with sustained release over 
more than 18 hours controlled by the erosion of water soluble 
polymer (hydroxypropyl methyl cellulose) from the matrix. 
Divalproex ER was approved in 2000 for the indication 
of migraine. The epilepsy indication was held up for two 
years as divalproex ER is not bioequivalent to divalproate 
delayed release (DR) (Depakote®; Abbott). A meta-anlysis 
of 5 multiple dose studies (Dutta and Zhang 2004) with 82 
healthy volunteers and 83 epilepsy patients compared dif-
ferent divalproex dosing regimens (2, 3, or 4 times per day) 
and meal conditions (fasting, low, medium, and high calorie 
meals). Fasting and food with varied caloric content had a less 
than 10% effect on divalproex ER availability. The estimated 
ratio of divalproex ER to divalproex DR and 95% conﬁ  dence 
intervals for AUC, Cmax, and Cmin was 0.89 (0.85–0.94), 0.79 
(0.74–0.84), 0.96 (0.90–1.02), respectively. When changing 
from divalproex to divalproex ER the recommendation was 
to increase the dose by 1/0.89 or 12%, to compensate for the 
overall decrease in AED exposure indicated by the differ-
ence in AUC. Thus, the recommendation for an 8%–20% 
increase in dose when changing to the ER formulation, the 
amount of increase determined by the nearest tablet size. 
A pooled analysis from 9 non-blinded, open label studies 
(5 epilepsy and 4 psychiatry) showed improved tolerability 
with divalproex ER with signiﬁ  cant reductions of tremor, 
weight gain, gastrointestinal symptoms, and hair loss. Two of 
the open label epilepsy trials reported a signiﬁ  cant reduction 
of seizures (Smith et al 2004).
The half-life of the routine divalproex formulation is 
about 14 hours in the absence of inducing drugs and decreases 
to about 9 hours in the presence of hepatic inducing drugs. 
The effects of concomitant enzyme-inducing AEDs on bio-
availability was investigated comparing divalproex DR dosed 
tid vs divalproex ER dosed 8%–20% higher as a single daily 
dose with the following effect on AUC, Cmax, Cmin: 1539 vs 
1551 mg/L, 92.6 vs 83.3 mg L, and 44.8 vs 45.8 mg/L. The 
difference in peak serum concentration was signiﬁ  cant. Thus, 
while the overall bioavailability of once daily divalproex ER 
is comparable with that achieved with thrice daily dosing of 
divalproex, the peak concentration achieved is less and there 
was a 64% peak to trough ﬂ  uctuation (Sommerville et al 
2003). The setting of concomitant inducing drugs may be 
where twice daily dosing of divalproex ER results in a ﬂ  atter 
serum concentration time curve with better tolerability and 
potential seizure control (Dutta and Reed 2006a, b). This is 
further supported by derivation of the “functional half-life” 
of divalproex ER which was 40 hours in the absence of 
hepatic inducers but decreased to 27 hours with concomitant Therapeutics and Clinical Risk Management 2008:4(5) 1039
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inducers, resulting in an approximate 50% reduction (absence 
of inducer) and 75% reduction (presence of inducer) from 
baseline trough serum concentration if one dose is missed 
and the next dose occurs 48 hours after the last dose (Dutta 
and Reed 2006a, b).
To summarize current experience with AED XR formula-
tions, they offer better tolerability. Improvement of seizure 
control has been demonstrated only in non-controlled, open-
label clinical trials. Choosing to dose a sustained release 
formulation approved for once daily dosing twice daily, 
may be more “forgiving” if a medication dose is missed and 
better tolerated in terms of adverse events, especially in the 
presence of concomitant enzyme inducers.
Lamotrigine and lamotrigine
XR pharmacokinetics
LTG, with a chemical name of 3, 5-diamino-6-(2, 3-dichlo-
rophenyl)-1,2,4-triazine, is a broad spectrum AED ﬁ  rst 
approved in Ireland in 1990 and the United States in 1994 
and now having over 5 million worldwide patient exposures. 
The immediate release formulation typically achieves a 
peak concentration 1.4–4.8 hours after oral dose. It has near 
complete bioavailability (98%). Protein binding is weak at 
about 55%. Drug interactions are essentially unidirectional 
with other drugs affecting the rate of LTG metabolism but 
not vice versa. In adult healthy volunteers and patients 
on LTG monotherapy mean half-life is about 24 hours 
after some autoinduction. Metabolism is affected by 
concomitant drugs. Half-life is shortened to a mean of 
12.6 hours in the presence of hepatic inducing drugs, 
such as phenytoin, carbamazepine, phenobarbital, and 
primidone, and less so by oxcarbazepine, and lengthened 
to a mean of about 60 hours in the presence valproic acid. 
Other drugs inducing LTG metabolism include synthetic 
estrogens and progestins, HIV protease inhibitors such as 
lopinavir and rotinavir, rifampin, sertraline, escitaloprim, 
risperidone, and gingko. Oral contraceptives have been 
shown to decrease LTG serum concentrations nearly 50% 
in a controlled study (Sabers et al 2003; Christensen et al 
2007). Concomitant administration of hepatic inducers and 
inhibitors produces a “pseudo-monotherapy” state, again 
a half-life of about 24 hours. Clearance is age-dependent, 
up to 2-fold faster in children compared with adults and 
slower in infants.
Metabolism is predominantly hepatic via glucuronida-
tion with 75%–90% recovered in urine as a 2-N-glucuronide 
derivative and minor additional metabolites, a 5-N-glucuronide, 
an N-2 methylated derivative, unidentified metabolites, 
and unchanged drug (Doig and Clare 1991; Sinz and 
Remmel 1991). Glucuronidation reactions are catalyzed by 
UDP-glucouryltransferase (UGT).
The UGTs exist as a super family of 117 enzymes 
divided into 4 families (UGT1, UGT2, UGT3, and UGT8) 
(Mackenzie et al 2005). UGTs conjugate a variety of 
substrates of endogenous, ie, bilirubin, steroid hormones, 
thyroid hormones, bile acids and fat soluble vitamins, and 
exogenous, drugs. UGT1A4 and UGT2B7 have major roles 
in N2-glucuronidation of LTG (Rowland et al 2006). Inter-
individual variability of glucuronidation would be expected 
to be at least 10-fold (Burchell et al 2001). Data from healthy 
volunteers and epilepsy patients supports a 5- to 10-fold 
inter-individual variability in lamotrigine clearance based on 
concentration to dose ratio (Armijo et al 1999; Hirsch et al 
2004; Bootsma et al 2008; Tompson et al 2008).
LTG-IR is usually dosed twice daily except in the pres-
ence of valproic acid where dosing may be once a day. In the 
absence of inducing agents the trough to peak ratio for imme-
diate release LTG would on average be 0.75 (t1/2∼24 hours) 
and in the presence of inducing agents 0.5 (t1/2∼12 hours). 
Minimal ﬂ  uctuation would be expected in the presence of 
the inhibitor valproic acid.
An extended release formulation of LTG has been 
developed and is currently being studied. LTG-XR tablets 
contain a modiﬁ  ed release eroding matrix formulation (Dif-
fCORE) designed to produce a steady dissolution rate over 
12–15 hours (Tompson et al 2008).
The pharmacokinetic proﬁ  le of LTG-XR in patients 
with epilepsy was recently published (Tompson et al 2008). 
Patients had a diagnosis of epilepsy, complex partial or gener-
alized seizures) and were already on a stable dose of LTG-IR 
(immediate release) prior to enrollment. The study had an 
open-label crossover design beginning with a 2-week base-
line on LTG-IR, followed by 2 weeks on LTG-XR, and then 
1 week follow-up back on LTG-IR. Forty-four subjects were 
enrolled with 3 equal groups of patients based on concomi-
tant AED effects on hepatic metabolism: neutral (n = 15), 
inducing (n = 15) or inhibiting (n = 14) LTG metabolism. 
Pharmacokinetic measures were steady state 24 hour serum 
concentration vs time curves (AUC (0–24)), Cmax, Cmin, Tmax 
(time to maximal serum concentration after oral dose), and 
ﬂ  uctuation index. Fluctuation index measures ﬂ  atness of 
the concentration time curve and is deﬁ  ned as (Cmax – Cmin) 
divided by the average serum concentration (Cavg). Data are 
given as the geometric mean (individual values are multiplied 
and then the nth root of the product is taken). Data varia-
tion was described by coefﬁ  cient of variation deﬁ  ned as the Therapeutics and Clinical Risk Management 2008:4(5) 1040
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standard deviation divided by the mean and then reported as 
a percentage by multiplying by 100. Coefﬁ  cient of variation 
is a dimensionless number allowing comparison between 
datasets with wildly different means.
LTG daily doses, mean and range, were 400 mg 
(200–600 mg), 600 mg (200–1200 mg), and 200 mg 
(50–800 mg) for the neutral, induced, and inhibited groups 
respectively. LTG-IR was given every 12 hours and compared 
with once daily dosing of LTG-XR. Median serum LTG con-
centration-time proﬁ  les over 24 hours for the two LTG formu-
lations are shown in Figure 1. For the neutral and especially 
for the induced groups, the LTG-XR formulation produced 
marked ﬂ  attening of the serum concentration-time curves, 
slower absorption rate and decreased ﬂ  uctuation. There 
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was no decrease of Cmin even on the ﬁ  rst day of transition to 
LTG-XR. The effect was minimal for the inhibited group.
The time to maximal serum concentration, Tmax, for 
LTG-IR was typically 1–1.5 hours for the three groups 
ranging from 0.5 to 6.13. Tmax was prolonged by LTG-XR 
for the neutral group to ten hours (range 0.00–24.00). Similar 
Tmax prolongation was noted for the inhibited group (mean 
9.08, range 2.88–24.00 hours) but was somewhat shorter for 
the induced group (mean 6.00, range 0.00–23.85 hours). AUC 
(0–24) was similar for the two LTG formulations with the 
exception of the group on concomitant inducers where it was 
reduced on average 21% lower for the XR formulation with 
90% conﬁ  dence interval between 10% and 31%. Steady-state 
Cmax on LTG-XR compared with LTG-IR was on average 
29% lower for the induced group compared to about 11% 
decrease for the neutral and inhibited groups. In contrast Cmin 
for the three groups was similar for both LTG preparations. 
As would be expected, the ﬂ  uctuation index during baseline 
on LTG-IR was lowest for the group on inhibitors (0.318), 
intermediate for the neutral group (0.545), and highest for the 
induced group (0.986). The ﬂ  uctuation index at steady-state 
LTG-XR was 0.209 for the inhibited, 0.341 for the neutral 
but 0.817 for the induced group. A dose normalized statistical 
analysis comparing the primary pharmacokinetic parameters 
showed that both AUC (0–24) and Cmax for the induced group 
was outside the 90% conﬁ  dence interval relative to the neutral 
and inhibited groups (Tables 2, 3). The small study did not 
observe a reduction of adverse events or improvement of 
seizure outcome in transitioning from LTG-IR to LTG-XR. 
However, over two-thirds (69%) of subjects reported a prefer-
ence for LTG-XR and 17% reported no preference leaving 
only 14% with a preference for twice daily dosing. 
Efﬁ  cacy for LTG-XR for partial seizures was demon-
strated against placebo in an add-on blinded study design 
(Naritoku et al 2007). The study included 238 patients 
(118 LTG-XR, 121 placebo) with a minimum of eight partial 
seizures during the 8-week baseline while on 1–2 baseline 
AEDs. Concomitant AEDs for the LTG-XR and placebo 
groups were carbamazepine (43% vs 42%), valproic acid 
(23% vs 35%), topiramate (16% vs 14%), oxcarbazepine 
(9 % vs 18%), phenytoin (14% vs 13%), and levetiracam 
(13% vs 11%). LTG-XR titration rate and target dose was 
adjusted to the presence of valproic acid (200 mg/day), 
enzyme-inducing AEDs (500 mg/day), and 300 mg for 
metabolically neutral drugs. Eighty percent of subjects 
randomized to LTG-XR compared with 87% to placebo 
Table 2 Summary of serum lamotrigine pharmacokinetic parameters (geometric mean and % CVb)
Formulation
Serum LTG PK parameter LTG-IR (day 14) LTG-XR (day 15) LTG-XR (day 28)
Induced
  AUC (0–24) (μgh/ml) 100 (85.9%) 92.0 (75.9%) 79.0 (100%)
 Cmax  (μg/ml) 6.71 (80.5%) 5.49 (64.1%) 4.77 (85.9%)
 Cmin  (μg/ml) 2.66 (100%) 2.51 (79.1%) 2.10 (131%)
  Fluctuation index 0.986 (40.1%) 0.780 (31%) 0.817 (50.0%)
  Tmax (h) 1.01 (0.50–298)a 6.00 (0.00–23.85)a 4.00 (0.00–24.00)a
Inhibited
  AUC (0–24) (μgh/ml) 208 (59.7%) 198 (62.8%) 167 (48.1%)
 Cmax  (μg/ml) 10.2 (57.5%) 9.37 (58.3%) 7.77 (49.0%)
 Cmin  (μg/ml) 7.44 (53.9%) 7.41 (57.6%) 6.32 (47.1%)
  Fluctuation index 0.318 (27.0%) 0.240 (44.3%) 0.209 (16.4%)
  Tmax (h) 1.00 (0.50–6.13)a 9.08 (2.88–24.00)a 11.00 (0.00–24.00)a
Neutral
  AUC (0–24) (μgh/ml) 142 (43.4%) 114 (44.3%) 138 (40.8%)
 Cmax  (μg/ml) 7.82 (39.3%) 5.80 (38.7%) 6.83 (38.6%)
 Cmin  (μg/ml) 4.57 (46.6%) 3.31 (66.4%) 4.87 (41.0%)
  Fluctuation index 0.545 (29.5%) 0.470 (62.2%) 0.341 (40.6%)
  Tmax (h) 1.50 (0.50–3.02)a 10.00 (0.00–24.00)a 6.00 (0.00–24.00)a
aTmax is presented as geometric mean and range.
Reproduced with permission from Tompson DJ,  Ali I,  Oliver-Willwong R, et al 2008.  Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-
release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia, 49:410–7. Copyright © 2008 Blackwell Publishing.Therapeutics and Clinical Risk Management 2008:4(5) 1042
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completed the study. During maintenance phase, 61.3% 
of subjects on LTG-XR vs 42.2% on placebo achieved at 
least a 50% reduction in seizure frequency. Adverse event 
rates were similar with 69% vs 62% reporting at least one 
adverse event except for dizziness (18% LTG-XR vs 5% 
placebo). Seventy-one percent reporting dizziness were 
on carbamazepine. This association has been previously 
reported. There were no differences between LTG-XR 
and placebo on health outcomes questionnaires (Proﬁ  le 
of Mood States, Epidemiologic Depression Scale, Quality 
of Life in Epilepsy-31-P, Liverpool Adverse Experience 
Proﬁ  le, Seizure Severity Questionnaire, and the Epworth 
Sleepiness Scale).
In summary, the pharmacokinetic data show similar 
parameters for AUC (0–24), Cmin, and Cmax for LTG-XR and 
LTG–IR in the presence of the inhibitor valproic acid or the 
absence of concomitant inducing AEDs. In the presence of 
inducing AEDs, the AUC and Cmax were reduced 20%–30% 
and the ﬂ  uctuation index, 0.817, was high compared with 
the absence of inducers, 0.341. Therefore, in the presence 
of inducing drugs, LTG-XR twice daily dosing should be 
considered, especially in patients more difﬁ  cult to control. 
The achieved more stable-serum concentration time curve 
may outweigh the modest increase of medication adher-
ence. The “average” patient on LTG-XR in the absence 
of inducing AEDs is likely to do very well. With the aver-
age 24 hour half-life of LTG, even missing a single dose 
is unlikely to be catastrophic in most patients. However, 
LTG clearance rate is highly variable, and patients who 
are rapid metabolizers, identiﬁ  ed by dose to concentration 
ratio, may also beneﬁ  t from the decreased ﬂ  uctuation of the 
serum concentration time curve achieved with twice daily 
dosing and the “forgiveness” of a missed dose. Children 
with their rapid metabolism may also beneﬁ  t from twice 
daily dosing.
In terms of beneﬁ  ts in seizure and tolerability, no differ-
ences were found in a small pharmacokinetic study directly 
comparing LTG-XR and LTG-IR. Therefore, no direct 
statement can be made though extrapolation to experience 
with divalproex and carbamazepine XR formulations 
anticipates beneﬁ  t.
Lamotrigine indications and uses
in epilepsy syndromes
LTG-IR was initially indicated as add-on therapy in partial 
epilepsies in adults and later in children above the age of two. 
A recent study has demonstrated efﬁ  cacy below two years of 
age down to one month of age (Pi ˇ  na-Garza et al 2008). In the 
pivotal clinical trials in adults, daily dosages between 200 and 
500 mg were studied. As most subjects were on concomitant 
enzyme-inducing AEDs, trough serum concentrations of 
only 1–4 μg/mL were achieved (Messenheimer et al1994). 
More recent data suggest that serum concentrations of at 
least 15 μg/mL are generally well tolerated (Froscher et al 
2002; Hirsch et al 2004; Morris et al 2004b). A pharmaco-
dynamic interaction of lamotrigine with valproate to improve 
seizure control when combined has been reported for partial 
seizures (Pisani et al 1999) and generalized seizures (Ferrie 
and Panyiotopoulos 1994).
LTG is also approved in the treatment of generalized 
seizures in Lennox-Gastaut (Motte et al 1997). It is also 
approved for conversion to monotherapy (Gilliam et al 
1998). With initiation of therapy, the slow upward titration 
has prohibited approval as initial therapy for epilepsy.
AEDs often have uses outside of epilepsy (Rogawski and 
Löscher 2004; Johannessen Landmark 2008). LTG has psy-
chiatric indication with controlled studies showing efﬁ  cacy in 
the treatment of bipolar disorder (Calabrese et al 2008).
LTG-XR has been shown to have efﬁ  cacy, compared 
with placebo, in partial epilepsies in adults to date. This is 
the initial indication submitted to the FDA. Ongoing studies 
are evaluating efﬁ  cacy in primary generalized tonic-clonic 
seizures (Biton et al 2008) and conversion to monotherapy. 
There is no reason to expect a different spectrum of activity 
than for the immediate release formulation.
Most AEDs have rarely been formally studied in con-
trolled, blinded designs of most speciﬁ  c epilepsy syndromes. 
LTG-IR has been described as having efﬁ  cacy in a number 
Table 3 Summary of statistical analysis of dose normalized steady-state lamotrigine parameters
Geometric least squares mean ratio (90% CI)
Serum LTG PK parameter Induced Inhibited Neutral
AUC (0–24) 0.79 (0.688, 0.899) 0.94 (0.810, 1.084) 1.00 (0.882, 1.140)
Cmax 0.71 (0.613, 0.823) 0.88 (0.750, 1.030) 0.89 (0.775, 1.026)
Cτ 0.99 (0.894, 1.094) 0.99 (0.884, 1.101) 1.14 (1.033, 1.252)
Reproduced with permission from Tompson DJ,  Ali I, Oliver-Willwong R, et al 2008.  Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-
release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia, 49:410–7. Copyright © 2008 Blackwell Publishing.Therapeutics and Clinical Risk Management 2008:4(5) 1043
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of generalized epilepsy syndromes in non-controlled designs 
(Gericke et al 1999). Open-label studies have reported efﬁ  -
cacy in childhood absence (Frank et al1999) and juvenile 
myoclonic epilepsy (Morris et al 2004a). LTG may worsen 
myoclonus in a subset of juvenile myoclonic epilepsy 
(Biraben et al 2000; Carrazana et al 2001). LTG has been 
reported to potentially worsen severe myoclonic epilepsy 
of infancy (Guerrini et al 1998).
Lamotrigine safety and tolerability
General tolerability
Overall LTG-IR was well tolerated compared to placebo 
in a meta-analysis of clinical trials with the odds ratio for 
withdrawal of 1.19 (CI 95%: 0.79, 1.79). Review of data 
from placebo-controlled add-on studies showed the following 
adverse events occurring a minimum of 3% more on LTG 
than on placebo: dizziness (35–5 = 20), diplopia (25–6 = 19), 
ataxia (20–6 = 14), nausea (19–9 = 10), blurred vision 
(13–4 = 9), somnolence (13–7 = 6), vomiting (10–5 = 5), 
abnormal coordination (6–2 = 4), tremor (5–1 = 4), insomnia 
(6–3 = 3), and rhinitis, (11–8 = 3). (Messenheimer et al 1998). 
Ataxia, diplopia, dizziness, and nausea occurred statistically 
more commonly with LTG treatment. Rash was noted in 10% 
on LTG and 5% in controls.
Rash
Rash was the most common serious adverse event observed in 
both the add-on and monotherapy clinical trials occurring in 
42 of 3071 subjects (1.4%) and 2 of 443 (0.5%). Most rashes 
were simple morbiliform. Rash leading to hospitalization 
occurred in 11 (0.3%) and 4 were Stevens-Johnson Syndrome 
(0.1%). Toxic-epidermal necrolysis and hypersensitivity 
syndrome have been reported.
Rash almost always occurs in the ﬁ  rst 8 weeks after the 
start of LTG therapy. In the epilepsy trials, rash incidence 
was related to the effects of the concomitant AEDs on 
LTG metabolism: highest in the presence of the inhibitor 
valproic acid (12.2%), lowest in the presence of inducing 
AEDs (2%) and with metabolically neutral AEDs (3%). 
These data suggest a concentration dependent effect. This 
was conﬁ  rmed by review of rash incidence in trials of all 
indications with initial LTG dose and rash rate as follows: 
25 mg (∼1%), 50 mg (∼9%), 100 mg (∼12%), and 200 mg 
(38%). The rate of upward titration also affects rash rate: 
at week ﬁ  ve, LTG dose 62.5 had a 1.5% incidence com-
pared with 12% at 375 mg/day. These results led to the 
manufacturer’s recommendation as to starting dose and 
upward titration rates for LTG in the presence of valproic 
acid, inducing AEDs, and neutral AEDs (Lamotrigine 
package insert 2007).
Decreasing the rate of initial titration was recommended 
by the manufacturer in 1993 and has dramatically decreased 
the incidence of rash, both benign (Hirsch et al 2006; Arif 
et al 2007) and serious (Kanner 2005; Mockenhaupt et al 
2005). A German population-based study, using an aca-
demically run registry to ascertain all hospitalized cases of 
Stevens-Johnson Syndrome and toxic epidermal necrolysis 
combined with identiﬁ  ed total and new users of lamotrigine 
via review of prescriptions claimed through the general 
health insurance plan covering 85% of the population, 
showed an incidence 5 cases per 4,450 exposures in 1993, 
2 of 7,610 exposures in 1994, and 3 of 17,648 exposures in 
1999. The rates of both benign and serious rash rate with 
initiation of LTG is now comparable to phenytoin, car-
bamazepine, phenobarbital, and zonisamide (Zonisamide 
package insert 2008).
Pregnancy: teratogenesis
and management
Until recently, counseling patients regarding the effects of 
AEDs on pregnancy outcome has relied on retrospective 
data that indicated a 2- to 3-fold increased risk in the inci-
dence of major malformations with the older AEDs (Holmes 
et al 2001; Perucca 2005b; Battino and Tomson 2007) with 
increasing risk on polytherapy, especially with valproic acid. 
The newer AEDs released since 1990 arrived with no data 
available to counsel women planning pregnancies. Therefore, 
multiple prospective registries have been established to ﬁ  ll 
this gap in information: national registries as the Swedish 
Medical Birth Registry and in Finland, independent academic 
registries as the North American Pregnancy registry, United 
Kingdom Register, European and International Registry 
of Antiepileptic Drugs and Pregnancy (EURAP) and the 
Australian Register, and pharmaceutical company registries. 
GlaxoSmithKline (GSK) began a pregnancy registry for 
women on LTG in 1992. More data are currently available 
for LTG than for any other new AED.
The GSK Lamotrigine pregnancy registry (2008) has 
accumulated 1155 outcomes involving first trimester 
monotherapy exposure and identiﬁ  ed 31 major malforma-
tions for a rate of 2.7% (95% CI: 1.9%–3.8%) compared 
with an estimated general population risk of 1.62% (95% 
CI 0.9%–2.3%) identiﬁ  ed by the Brigham and Women’s 
Surveillance program and Metropolitan Atlanta Congeni-
tal Defects Program. The registry is currently powered to 
detect a 1.6-fold increase in monotherapy associated Therapeutics and Clinical Risk Management 2008:4(5) 1044
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risk (The Lamotrigine Pregnancy Registry Interim Report 
1 September 1992 through 30 September 2007). Similar 
malformation rates are reported in the UK registry (3.2%, 
n = 647, 95% CI: 2.1%–4.9%) and North American registry 
(2.3%, n = 684, 95% CI: 0.9%–3.8%) (Holmes et al 2008).
The UK pregnancy registry suggests a dose-dependent 
effect of LTG seen by 200 mg/day or more (Morrow et al 
2008). Dose-dependence has not been conﬁ  rmed by the GSK 
registry in daily doses up to 400 mg with insufﬁ  cient data 
at higher doses (Cunnington et al 2007) or for the North 
American registry (Holmes et al 2008).
An increased occurrence of facial cleft has been reported 
in two registries. The Swedish Medical Birth Registry found 
a cleft palate rate in 90 ﬁ  rst trimester LTG monotherapy 
exposures of 9.9 per 1000 compared to an expected rate of 
2 per 1000; relative rate 4.5% (95% CI: 2.7%–7.1%). The 
North American Pregnancy Registry also identiﬁ  ed a speciﬁ  c 
increase in non-syndromic cleft palates with LTG: in 684 
outcomes there were three isolated cleft palates, one cleft 
lip, and one cleft palate plus cleft lip for a combined rate of 
7.3/1000 compared to a rate in the comparison population 
of 0.7/1000 (Holmes et al 2008). The comparator group was 
historical and taken from the Active Malformations and 
Surveillance Program at Brigham and Women’s Hospital in 
Boston with 206,224 infants and elective pregnancy termina-
tions accumulated between 1972–1974 and 1979 and 2000. 
The rates of facial cleft were 1 in 647 outcomes for a rate 
of 2/1000 in the UK registry (Morrow et al 2006), 2 in 707 
for a rate of 3/1000 in the GSK International Registry, 0 in 
128 outcomes in the Australian Pregnancy Registry, and 0 
of 51 outcomes in the Danish Multicentre Registry (Holmes 
et al 2008).
Overall multiple registries have power to exclude a 2- to 
3-fold increase in major malformations by LTG. An increase 
in speciﬁ  c defects can not be excluded and several registries 
have noted an increased rate of facial clefts. There are major 
differences in the design of the registries that may account 
for differences in outcome (Tomson et al 2007; French et al 
2008). Firm conclusions will require identiﬁ  cation of similar 
outcomes across registries. Studies of the effects of neonatal 
AED exposure on cognition are ongoing (Meador et al 2006; 
Tomson and Battino 2008).
LTG has been associated with increased frequency of sei-
zures during pregnancy. This observation has been attributed 
to increased clearance of LTG with declining serum concen-
trations during pregnancy. The increase in LTG clearance 
is substantial with reports ranging from about 94% to 250% 
(Öhman et al 2008; Pennell et al 2008).
Quality of life
About 30% of patients complain of medication side effects, 
most commonly tiredness and cognition (Gilliam et al 1997, 
Fisher et al 2000). Speciﬁ  c complaints in decreasing order 
of report were problems of cognition, energy level, school 
performance, childbearing, coordination, and sexual function 
(Fisher et al 2000). Mood is also a strong predictor of health 
assessment in patients with epilepsy.
LTG has been compared to phenytoin, carbamazepine, 
valproic acid, and topiramate in double-blind, controlled 
trials of intractable epilepsy, new onset epilepsy or healthy 
volunteers. These studies have consistently found better 
cognitive status based on objective measures as well as 
improved quality of life and mood on subjective inventories 
(Cohen et al 1985; Gillham et al 2000; Sackellares et al 2002; 
Meador et al 2005; Blum et al 2006; Meador 2006). Similar 
observations are noted in open label trials. LTG has also 
been associated with improved sexual function in women 
and men (Gil-Nagel et al 2006).
Conclusions
LTG is a broad spectrum AED that is typically dosed twice a 
day with good overall tolerability. In the presence of valproic 
acid which inhibits metabolism via glucuronidation, LTG 
may easily be dosed once per day. LTG-XR is an improved 
formulation that will be approved for once daily dosing. 
Extrapolating to experience with other extended release for-
mulations, this should lead to improved tolerability, patient 
preference, compliance, and possibly seizure control. How-
ever, in patients with rapid metabolism or on concomitant 
hepatic inducing drugs, there is signiﬁ  cant serum concentra-
tion ﬂ  uctuation plus a lack of forgiveness for a missed dose 
of medication. Twice daily dosing in these patients may 
improve therapeutic coverage outweighing the modest 
decline of adherence. Overall, LTG XR is a welcome agent 
to our AED armamentarium.
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